HUTCHMED DRC
$ 10.84
-6.63%
17 Jul - close price
- Market Cap 1,996,344,000 USD
- Current Price $ 10.84
- High / Low $ 11.02 / 10.83
- Stock P/E 4.38
- Book Value 7.20
- EPS 2.65
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE 0.45 %
- 52 Week High 19.50
- 52 Week Low 9.77
About
HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
Analyst Target Price
$22.62
Quarterly Earnings
| Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-06-18 | 2025-11-28 | 2025-07-02 | 2025-05-28 | 2025-03-19 | 2024-11-29 | 2024-07-31 | 2024-06-10 | 2024-02-28 | 2023-11-10 | 2023-07-31 | 2023-06-20 |
| Reported EPS | None | 0 | 0.52 | 0 | 0.01 | 0 | 0 | 0 | -0.7 | 0 | 0.97 | 0 |
| Estimated EPS | None | 0 | 0 | 0 | 0.04 | 0 | 0 | 0 | -1.08 | 0.04 | -0.055 | -0.05 |
| Surprise | 0 | 0 | 0.52 | 0 | -0.03 | 0 | 0 | 0 | 0.38 | -0.04 | 1.025 | 0.05 |
| Surprise Percentage | None% | None% | None% | None% | -75% | None% | None% | None% | 35.1852% | -100% | 1863.6364% | 100% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HCM
2026-07-16 00:10:10
HUTCHMED (China) Ltd (HCM) shares surged 3.0% to $11.60 on July 15, 2026. The company is considered modestly undervalued with a GF Value™ of $13.72, and its GF Score™ of 79/100 indicates above-average performance with strong growth and valuation, despite lower profitability. No insider transactions were reported in the last three months.
2026-07-08 04:10:38
BofA Securities has reiterated its Buy rating for Hutchmed (China) (HCM.US) but has adjusted its target price downwards to $17. This indicates continued confidence in the company's prospects despite a revised valuation.
2026-07-03 04:10:38
HUTCHMED (China) Limited announced that its drug ORPATHYS® (savolitinib) received conditional approval from China's National Medical Products Administration (NMPA) for treating advanced gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who have failed previous systemic treatments. This approval marks a significant advancement in precision medicine for gastrointestinal oncology in China, addressing a high unmet medical need. The decision is supported by positive data from a pivotal Phase II study, highlighting the drug's efficacy and HUTCHMED's commitment to innovation.
2026-07-03 03:09:50
HUTCHMED shares surged by 6.5% following the conditional approval of its drug ORPATHYS® (savolitinib) in China for advanced gastric cancer or gastroesophageal junction adenocarcinoma. This marks the first selective MET inhibitor approved for this patient population in China, targeting about 18,000 annual cases. The approval was based on positive Phase II study data showing a 32.3% objective response rate, and it represents the third indication for ORPATHYS® in the country.
2026-07-02 13:25:39
Hutchmed China Ltd has received conditional approval from China's NMPA for its drug savolitinib ('ORPATHYS') to treat advanced gastric cancer patients with MET amplification, a condition with poor prognosis. This marks the drug's third approved indication in China and is a joint development with AstraZeneca PLC. Following the announcement, Hutchmed's shares jumped 11% in London.
2026-07-02 12:40:41
HUTCHMED (NASDAQ:HCM) has received conditional approval from China's National Medical Products Administration for its cancer drug ORPATHYS (savolitinib). This approval is for the treatment of MET-amplified advanced gastric or gastroesophageal junction adenocarcinoma in patients who have undergone at least two prior systemic therapies. The decision was based on Phase II clinical study results showing a 32.3% objective response rate and a median progression-free survival of 4 months.
